Drug Type Small molecule drug |
Synonyms ERK-IN-1, LTT-462 |
Target |
Mechanism ERK1 inhibitors(Extracellular-signal-regulated kinase1 inhibitors), ERK2 inhibitors(Extracellular-signal-regulated kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Molecular FormulaC26H27BrF3N5O2 |
InChIKeyYFCIFWOJYYFDQP-PTWZRHHISA-N |
CAS Registry1715025-32-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
BRAF V600 mutant Colorectal Cancer | Phase 1 | US | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | AU | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | BE | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | CA | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | DE | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | IL | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | NL | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | SG | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | ES | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | GB | 22 Jul 2020 |
Phase 1 | NRAS Mutant Melanoma | KRAS mutant Non-small Cell Lung Cancer | BRAF Mutation Non-small Cell Lung Cancer KRAS Mutation | BRAF Mutation | NRAS Mutation | 216 | pfgpprufiw(xasckrluae) = wlelrdlgrb zgiglvfxjj (fysrzrhqhd ) View more | Negative | 01 Nov 2024 | ||
pfgpprufiw(xasckrluae) = ebvlkmdijp zgiglvfxjj (fysrzrhqhd ) View more |